Introduction

Approximately half of extremely preterm infants have bronchopulmonary dysplasia (BPD). One-quarter of these infants are prescribed home oxygen, yet compliance with home pulse oximetry is low. Despite parental reports of frequent alarms contributing to premature monitor discontinuation, limited data exist to inform home alarm configuration and reduce unnecessary alarms. In a small observational study of a heterogenous pediatric population, longer alarm delays were associated with decreased alarm incidence. The true burden of home oximeter alarms and the impact of alarm parameters on alarm incidence are unknown in patients with BPD. Our objective was to evaluate the association of low oxygen saturation (SpO₂) limits, alarm delays, and averaging times with alarm incidence by simulating threshold adjustments using data from a clinical trial of continuous home SpO₂ monitoring among infants with BPD.

Table. Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients, No. (%) (N = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth gestational age, mean (SD), wk</td>
<td>26.1 (1.9)</td>
</tr>
<tr>
<td>Severity of BPD</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Severe</td>
<td>19 (95)</td>
</tr>
<tr>
<td>PMA at hospital discharge, mean (SD), wk</td>
<td>47.4 (5.2)</td>
</tr>
<tr>
<td>Respiratory support at hospital discharge</td>
<td></td>
</tr>
<tr>
<td>Nasal cannula</td>
<td>10 (50)</td>
</tr>
<tr>
<td>Room air</td>
<td>10 (50)</td>
</tr>
<tr>
<td>Length of monitoring, mean (SD), h²</td>
<td>114.9 (80.7)</td>
</tr>
</tbody>
</table>

Abbreviations: BPD, bronchopulmonary dysplasia; PMA, postmenstrual age.

* BPD severity defined according to 2001 Jobe and Bancalari National Institutes of Health Workshop. Moderate BPD was defined as 28 days of oxygen plus fraction of inspired oxygen of less than 30% at 36 weeks’ PMA or discharge; severe, 28 days of oxygen plus fraction of inspired oxygen of 30% or greater and/or positive pressure at 36 weeks’ PMA or discharge.

* Length of nonzero oxygen saturation monitoring.
Methods

The BPD Saturation Targeting Trial is an ongoing randomized clinical trial (NCT03385330) in which preterm infants with moderate or severe BPD undergo SpO2 monitoring (Masimo Rad-8) while asleep from 34 to 44 weeks' postmenstrual age (PMA) to 6 months' corrected age. In this secondary study, we used home oximeter data acquired during the first 4 weeks after discharge. Patients with 8 hours or more of usable data were included. Because no events requiring emergency intervention were reported while patients were on study monitors, all SpO2 readings of zero were considered artifact and excluded from analysis. We used the raw data to estimate counts of low SpO2 alarms that would occur with SpO2 limits of 80%, 85%, and 90%; alarm delays of 0, 5, 10, and 15 seconds; and averaging times of 8 and 16 seconds. We tested for linear trends in the rate of alarms per 8 hours (to estimate number of alarms per night) using the Cuzick test. Parents provided written informed consent for enrollment in this study approved by the Children's Hospital of Philadelphia institutional review board. This study followed the STROBE reporting guideline.

Results

Twenty infants with mean (SD) discharge PMA of 47.4 (5.2) weeks were included (Table). The Figure depicts the estimated number of alarms per 8 hours across SpO2 limits and alarm delays with 8- and 16-second averaging times. Under typical postdischarge oximeter settings at our institution (90% limit, 0-second delay, 8-second averaging time), patients would experience a median (IQR) of 23.1 (16.0-53.0) alarms per 8 hours. Patients would experience a median of less than 1 alarm per 8 hours with an SpO2 limit of 80%, 15-second delay, and averaging time of 8 or 16 seconds. Within each delay, lower SpO2 limits were associated with lower alarm rates for both 8- and 16-second averaging times ($P < .001$). Within a given SpO2 limit, longer alarm delays were associated with lower alarm rates (8-s averaging time: $P < .001$ for all SpO2 limits; 16-s averaging time: 80%, $P < .001$; 85%, $P = .001$; 90%, $P = .003$). With a 0-s delay and a 90% SpO2 limit, there was no significant difference in alarms per 8 hours between 8- and 16-second averaging times.

Discussion

We used patient-level data to demonstrate the burden of low SpO2 alarms among infants with BPD who are monitored at home. Furthermore, we showed the association of alarm parameters with alarm incidence. Current science suggests prolonged—but not necessarily brief—intermittent hypoxemia episodes with an SpO2 below 80% are associated with poor developmental outcomes in convalescing extremely preterm infants.6 Broadening SpO2 limits and/or adding alarm delays can significantly decrease alarm rates while preserving alarms for episodes of potentially critical hypoxemia. Typical home oximeter settings (90% limit, 0-s delay) seem to create an untenable alarm burden for caregivers. Study limitations include sample size and use of simulated alarms. Future studies need to assess the outcome of liberalizing home parameters to reduce alarm rates, which may include more uninterrupted sleep, decreased caregiver alarm fatigue, and improved compliance with home monitoring to optimize health and developmental outcomes.
Corresponding Author: Heidi M. Herrick, MD, MSCE, Division of Neonatology, Department of Pediatrics, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, 2nd Floor, Main Building, Philadelphia, PA 19104 (herrickh@chop.edu).

Author Affiliations: Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia (Herrick, Bonafide, DeMauro); Division of Neonatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (Herrick, DeMauro); Roberts Center for Pediatric Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (Passarella); PRECISE Center, Department of Computer and Information Science, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia (Weimer); Section of Hospital Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (Bonafide).

Author Contributions: Dr DeMauro and Ms Passarella had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Herrick, Bonafide, DeMauro.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Herrick.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Passarella.

Obtained funding: Bonafide, DeMauro.

Administrative, technical, or material support: Weimer.

Supervision: DeMauro.

Conflict of Interest Disclosures: Ms Passarella reported receiving grants from the Agency for Healthcare Research and Quality and the National Institutes of Health outside the submitted work. Dr Weimer reported receiving grants from the National Science Foundation, Defense Advanced Research Projects Agency, the Office of Naval Research, the Air Force Research Laboratory, the Coulter Foundation, and the Agency of Healthcare Research and Quality outside the submitted work. Dr DeMauro reported receiving grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported.

Funding/Support: Efforts contributing to this manuscript were supported in part by award 14171 from the Thrasher Research Fund and award R18HS026620 from the Agency for Healthcare Research and Quality. Ms Passarella and Dr DeMauro are supported the Thrasher Research Fund, and Drs Herrick, Bonafide, and DeMauro are supported by the Agency for Healthcare Research and Quality.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


